The CXCL12 G801A Polymorphism is Associated with Cancer Risk: a Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Oct 1

PMID 25268356

Citations 9

Authors

Ke Zhu

Benchun Jiang

Rong Hu

Ying Yang

Miao Miao

Yingchun Li

Zhuogang Liu

Affiliations

Soon will be listed here.

Abstract

Background: CXCL12 is a small chemotactic cytokine belonging to the CXC chemokine family expressed in various organs. It contributes to the migration, invasion and angiogenesis of cancer cells. Recently, the CXCL12 G801A polymorphism was shown to be associated with an increased risk of various kinds of cancers, but the results were too inconsistent to be conclusive.

Methods: To solve the problem of inadequate statistical power and conflicting results, a meta-analysis of published case-control studies was performed, including 4,435 cancer cases and 6,898 controls. Odds ratios (ORs) and their 95% confidence intervals (CIs) were used to determine the strength of association between CXCL12 G801A polymorphism and cancer risk.

Results: A significant association between CXCL12 G801A polymorphism and cancer risk was found under all genetic models. Further, subgroup analysis stratified by ethnicity suggested a significant association between CXCL12 G801A polymorphism and cancer risk in the Asian subgroup under all genetic models. However, in the Caucasian subgroup, a significant association was only found under an additive genetic model and a dominant genetic model. The analysis stratified by cancer type found that CXCL12 G801A polymorphism may increase the risk of breast cancer, lung cancer, and "other" cancers. Based on subgroup stratified by source of controls, a significant association was observed in hospital-based studies under all genetic models.

Conclusions: The CXCL12 G801A polymorphism is associated with an increased risk of cancer based on current published data. In the future, large-scale well-designed studies with more information are needed to better estimate possible gene-gene or gene-environment interactions.

Citing Articles

Association of the CXCL12 rs1801157 Polymorphism with Breast Cancer Risk: A Meta-Analysis.

Alijanpour A, Golshan A, Vakili-Ojarood M, Shirinzadeh-Dastgiri A, Naseri A, Karimi-Zarchi M Asian Pac J Cancer Prev. 2024; 25(3):767-776.

PMID: 38546059 PMC: 11152371. DOI: 10.31557/APJCP.2024.25.3.767.

Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.

Lin S, Zheng Y, Wang M, Zhou L, Zhu Y, Deng Y Mol Biol Rep. 2022; 49(3):2255-2263.

PMID: 35079936 PMC: 8863681. DOI: 10.1007/s11033-021-07047-9.

Genetic Modifiers of the Breast Tumor Microenvironment.

Flister M, Bergom C Trends Cancer. 2018; 4(6):429-444.

PMID: 29860987 PMC: 5990047. DOI: 10.1016/j.trecan.2018.04.003.

The CXCL12 rs1801157 polymorphism and risk of colorectal cancer: a meta-analysis.

Xu K, Dai H, Wang S, Zhang J, Liu T Onco Targets Ther. 2018; 11:2445-2452.

PMID: 29760554 PMC: 5937488. DOI: 10.2147/OTT.S151514.

Relationship between rs1801157 polymorphism in stromal cell-derived factor gene and systemic lupus erythematosus risk.

Qian C, Zou Q, Wang Y Oncotarget. 2017; 8(43):75509-75515.

PMID: 29088886 PMC: 5650441. DOI: 10.18632/oncotarget.19766.

References

de Oliveira K, Oda J, Voltarelli J, Nasser T, Ono M, Fujita T . CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal. 2009; 23(6):387-93. PMC: 6649101. DOI: 10.1002/jcla.20346. View

Zhang Y, Long J, Lu W, Shu X, Cai Q, Zheng Y . Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2014; 23(4):622-8. PMC: 3976694. DOI: 10.1158/1055-9965.EPI-13-1043. View

Kato M, Kitayama J, Kazama S, Nagawa H . Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003; 5(5):R144-50. PMC: 314431. DOI: 10.1186/bcr627. View

Singh V, Jaiswal P, Kapoor R, Kapoor R, Mittal R . Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. Tumour Biol. 2014; 35(5):4765-72. DOI: 10.1007/s13277-014-1624-7. View

Kerdivel G, Le Guevel R, Habauzit D, Brion F, Ait-Aissa S, Pakdel F . Estrogenic potency of benzophenone UV filters in breast cancer cells: proliferative and transcriptional activity substantiated by docking analysis. PLoS One. 2013; 8(4):e60567. PMC: 3617139. DOI: 10.1371/journal.pone.0060567. View

Li N, Zhou P, Zheng J, Deng J, Wu H, Li W . A polymorphism rs12325489C>T in the lincRNA-ENST00000515084 exon was found to modulate breast cancer risk via GWAS-based association analyses. PLoS One. 2014; 9(5):e98251. PMC: 4039483. DOI: 10.1371/journal.pone.0098251. View

Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A . SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res. 2008; 14(1):45-50. DOI: 10.1007/s12253-008-9007-2. View

Ma Q, Jones D, Borghesani P, Segal R, Nagasawa T, Kishimoto T . Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998; 95(16):9448-53. PMC: 21358. DOI: 10.1073/pnas.95.16.9448. View

Gong H, Tan M, Wang Y, Shen B, Liu Z, Zhang F . The CXCL12 G801A polymorphism and cancer risk: evidence from 17 case-control studies. Gene. 2012; 509(2):228-31. DOI: 10.1016/j.gene.2012.08.018. View

10.

Schimanski C, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V . Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005; 11(5):1743-50. DOI: 10.1158/1078-0432.CCR-04-1195. View

11.

Bleul C, Fuhlbrigge R, Casasnovas J, Aiuti A, Springer T . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996; 184(3):1101-9. PMC: 2192798. DOI: 10.1084/jem.184.3.1101. View

12.

Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K . CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004; 3(1):29-37. View

13.

de Oliveira K, Guembarovski R, Guembarovski A, do Amaral Herrera A, Jorge Sobrinho W, Ariza C . CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer. Clin Exp Med. 2012; 13(3):211-9. DOI: 10.1007/s10238-012-0194-5. View

14.

Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh J . Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 2001; 97(11):3354-60. DOI: 10.1182/blood.v97.11.3354. View

15.

de Oliveira K, Guembarovski R, Oda J, Mantovani M, Carrera C, Reiche E . CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine. 2011; 55(2):260-5. DOI: 10.1016/j.cyto.2011.04.017. View

16.

Lin G, Tseng H, Yang C, Hou M, Chuang L, Tai H . Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS. 2009; 13(2):165-72. DOI: 10.1089/omi.2008.0050. View

17.

Lane W, Dias S, Hattori K, Heissig B, Choy M, Rabbany S . Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000; 96(13):4152-9. View

18.

Petit I, Jin D, Rafii S . The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007; 28(7):299-307. PMC: 2952492. DOI: 10.1016/j.it.2007.05.007. View

19.

de Lourdes Perim A, Guembarovski R, Oda J, Lopes L, Ariza C, Amarante M . CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL). Mol Biol Rep. 2013; 40(7):4591-6. DOI: 10.1007/s11033-013-2551-1. View

20.

Sei S, Boler A, Nguyen G, Stewart S, Yang Q, Edgerly M . Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS. 2001; 15(11):1343-52. DOI: 10.1097/00002030-200107270-00003. View